Cognition Therapeutics Reports Q1 2026 Financial Results

What Happened Cognition Therapeutics, Inc. (CGTX) filed a Form 8-K on May 7, 2026, to announce and furnish a press release reporting its financial results for the quarter ended March 31, 2026. The press release is included as Exhibit 99.1 to the filing; the body of the 8-K refers investors to that release for the detailed quarterly results.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02 — Results of Operations and Financial Condition).
• Reporting period: Quarter ended March 31, 2026.
• Exhibit: Press release dated May 7, 2026 furnished as Exhibit 99.1; Inline XBRL cover page (Exhibit 104) embedded.
• The 8-K itself does not present line-item financial figures in the text — see Exhibit 99.1 for revenue, net income/loss, cash balances, and any management commentary.

Why It Matters This filing signals that Cognition Therapeutics has publicly reported its most recent quarterly earnings and financial condition. For investors, the press release will contain the specific numbers (earnings, revenue, R&D and operating expenses, cash runway or guidance) that affect valuation and near-term expectations. Retail investors should review Exhibit 99.1 to see the company's reported results and any management statements before making investment decisions.